Author

Marco Pizzi

University of PaduaORCID 0000-0003-4006-7317Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Assay:ChIP-seq· 1

Frequent Co-Authors

Alberto J. ArribasiD· 2 shared Francesco BertoniiD· 2 shared Giulio SartoriiD· 2 shared Luciano CascioneiD· 2 shared Sara NapoliiD· 2 shared Adrian AndronacheiD· 1 shared Alessandra TucciiD· 1 shared Alessandro Ghiringhelli· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alberto J. ArribasORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 5, 2026

The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle, immune evasion, and snoRNA processing in activated B-cell-like diffuse large B-cell lymphoma cells

Giulio Sartori, Valdemar Priebe, Luciano Cascione…·Francesco Bertoni

This study identifies DDX21 as a key effector of ETS1/FLI1 in ABC-DLBCL, linking it to cell cycle, immune evasion, and snoRNA processing, with potential therapeutic implications.

DOI 10.64898/2026.06.02.729583

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyBlood Cancer DiscoveryPeer-reviewedMay 22, 2025

B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements

Gabriele Varano, Silvia Lonardi, Paola Sindaco…·Stefano S Casola

This paper shows that high-grade B cell lymphomas with MYC and BCL2 rearrangements originate from BCR-silenced follicular lymphoma cells that acquire IGL::MYC translocations, leading to resistance to CD79B-targeting therapy.

10 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 17, 2024

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

Filippo Spriano, Luciano Cascione, Jacopo Sgrignani…·Francesco Bertoni

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky